Skip to main content
. 2022 May 10;11(10):2697. doi: 10.3390/jcm11102697

Table 1.

Patient characteristics.

SCT, n = 59 (15.1%) LCT, n = 331 (84.9%) p-Value
Age (median) (range) 81 (26–100) 81 (25–102) 0.837
Sex (male:female) 28:31 172:159 0.579
Cause of cholangitis
Malignant stricture 17 (28.8%) 85 (25.7%) 0.631
Bile duct stone 36 (61.0%) 216 (65.3%) 0.556
Benign bile duct stricture 3 (5.1%) 8 (2.4%) 0.223
Chronic pancreatitis 1 (1.7%) 4 (1.2%) 0.562
Mirizzi syndrome 0 (0.0%) 9 (2.7%) 0.366
Autoimmune pancreatitis 1 (1.7%) 1 (0.3%) 0.28
Others 1 (1.7%) 8 (2.4%) >0.99
Severity
Mild 32 (54.2%) 151 (45.6%) 0.258
Moderate 27 (45.8%) 180 (54.4%) 0.258
Bil ≥ 5.0 (mg/dL) 11 (18.6%) 72 (21.8%) 0.73
WBC < 4000, 12,000 < WBC (/μL) 14 (23.7%) 111 (33.5%) 0.173
Alb < 3.0 (g/dL) 18 (30.5%) 100 (30.2%) >0.99
NEWS (median) (range)
On admission 1 (0–7) 1 (0–13) 0.096
Just before ERCP 1 (0–7) 1 (0–13) 0.159
48 h after ERCP 0 (0–5) 0 (0–6) 0.429
Underlying disease
CKD 5 (8.5%) 26 (7.9%) 0.797
CHF 2 (3.4%) 34 (10.3%) 0.139
LC 3 (5.1%) 15 (4.5%) 0.743
DM 8 (13.6%) 62 (18.7%) 0.461
Malignant tumor 18 (30.5%) 92 (27.8%) 0.642
Patient background
Nursing home 7 (11.9%) 70 (21.1%) 0.112
Hemodialysis 0 (0.0%) 8 (2.4%) 0.613
Gastrostomy 1 (1.7%) 1 (0.3%) 0.28
Constant placement of urinary catheter 0 (0%) 2 (0.6%) >0.99
Aspiration pneumonia 0 (0%) 7 (2.1%) 0.601
Immunosuppressant 0 (0%) 6 (1.8%) 0.597
Re-intervention to bile duct stent 11 (18.6%) 65 (19.6%) >0.99

Some cases overlapped. SCT: short-course antibiotic therapy; LCT: long-course antibiotic therapy; Bil: bilirubin; WBC; white blood cells; Alb: albumin; NEWS: national early warning score; ERCP: endoscopic retrograde cholangiopancreatography; CKD: chronic kidney disease; CHF: chronic heart failure; LC: liver cirrhosis; DM: diabetes mellitus.